cerebral infarction, and the timing and method of aneurysm repair, have also been shown to influence outcome after SAH. 6, 30, 36, 38 While patient demographics and the extent of neurological injury remain the strongest predictors of outcome following SAH, interregional and cross-national disparities may also contribute to heterogeneities in patient outcomes. 31 Such differences may be related to the expertise of the treating physician and the volume of SAH encountered within the institution, 2 or may be secondary to discrepancies in treatment protocols for common SAH complications, including hydrocephalus and vasospasm. 6 It is also increasingly recognized that socioeconomic factors may be linked to patient outcomes following SAH. 20 In this study, we performed an exploratory analysis of a large database of patients enrolled in studies of tirilazad mesylate to evaluate the association between selected socioeconomic indicators of the country of treatment and patient outcomes following SAH. To test these associations, we used a hierarchical or multilevel mixedeffects analysis, in which patients were modeled not as independent observations, but rather, as being nested within countries, thereby allowing variance between countries of treatment to be modeled theoretically. We collected national socioeconomic indicators, namely the population-to-neurosurgeon ratio, health care funding model (private, public, or mixed), and per-capita gross domestic product (GDP) as higher-level covariates. As opposed to patient-level predictors, such as initial neurological grade or severity of radiographic findings, socioeconomic indicators are often amenable to modification, therefore the identification of significant associations may lead to policies that can improve outcome following intracranial aneurysm rupture.
Methods

Study Database
Analysis was performed on a database of 3552 patients enrolled in 5 studies of the aminosteroid tirilazad mesylate following aneurysmal SAH, for reduction of symptomatic vasospasm, from 1991 to 1997. The studies were performed across 162 neurosurgical centers in 21 countries in North and Central America, Australia, Europe, and Africa. 13, 14, 21, 24, 25 The studies included patients 18 years of age or older with angiographically confirmed saccular aneurysms and CT-or lumbar puncture-confirmed SAH, with admission to the hospital within 48 hours of hemorrhage. Patients with traumatic, fusiform, or mycotic cerebral aneurysms, and serious atherosclerotic, arrhythmic, or functional cardiac disease were excluded, as were patients who previously received corticosteroid therapy.
Patients were randomized to receive placebo or 2, 6, or 15 mg/kg/day of tirilazad mesylate, starting within 72 hours and continuing up to 10 days after SAH. All patients received intravenous nimodipine as standard treatment. The timing of surgical clipping of aneurysms was at the discretion of the treating physician. No aneurysms were secured by endovascular coiling.
Explanatory Variables
Because we considered the data set hierarchically structured, with patients nested within individual countries, the explanatory variables included in the statistical models consisted of patient-level (or first-level) and nation-level (or second-level) covariates. Patient-level covariates consisted of clinical and radiological characteristics of individual patients collected in the tirilazad database. Clinical variables included patient age, sex, history of hypertension or myocardial infarction, initial neurological grade based on the World Federation of Neurological Societies (WFNS) scale 10 dichotomized into good (WFNS I-III) and poor (WFNS IV-V) grades, as well as time from hospital admission to aneurysm clipping, and the use of "triple-H" therapy (hypertension, hypervolemia, and hemodilution; HHH) during admission. HHH therapy was recorded according to the modality used (hypervolemia, hemodilution, or induced hypertension). Radiographic variables included subarachnoid clot burden on initial CT scan, as well as hydrocephalus and intracerebral or intraventricular hemorrhage on the admission CT scan. Aneurysm size, as well as angiographic vasospasm and radiographic cerebral infarction, were also included. These variables were chosen as explanatory variables based on previously correlative studies showing associations between these variables and patient outcome. 6, 15, 18, 36 Nation-level covariates consisted of 3 standard socioeconomic indicators that were deemed important a priori by the authors and merged into the tirilazad database: health care funding model (public, private, or mixed), population-to-neurosurgeon ratio (unit population per 1 neurosurgeon), and per-capita GDP (in US dollars). Data for per-capita GDP were obtained from the World Bank online database and averaged from 1991 to 1997, the study enrollment dates (http://data.worldbank.org/indicator/NY. GDP.PCAP.CD) (http://data.worldbank.org/indicator/SH. XPD.PCAP). Funding models were determined to be public if ≥ 70% of total health care expenditure was from public funds, private if public health expenditure was < 30%, and mixed if public expenditure was between 30% and 70%, as per World Bank data averaged from 1991 to 1997 (http://data.worldbank.org/indicator/SH. XPD.PUBL). Information on population-to-neurosurgeon ratio was obtained from combined data from the WHO, Canadian Neurosurgical Society, and Union Européenne des Médecins Spécialistes Section on Neurosurgery. 17, 34 Given the large number of first-level observations (3552 individual patients) relative to second-level observations (21 countries), we restricted the national-level covariates to these 3 key socioeconomic indicators, to mitigate the possibility of a Type II error. 22 To test whether significant associations involving population-to-neurosurgeon ratio were related to centralization of care, data on the number of neurosurgical centers per unit population were also collected and included in the tirilazad database for nations with available data: Australia, Canada, Denmark, Finland, Germany, Italy, Norway, Sweden, and Switzerland. 5, 7, 12, 29, 40 As a validation study, statistical models were reanalyzed using the variable "centers per population" as a nation-level (sec-ond-level) covariate in place of the population-to-neurosurgeon ratio.
Response Variables
Two primary outcomes were assessed at 3 months following SAH: mortality, dichotomized as alive versus dead, and neurological outcome, as assessed by the 5-point Glasgow Outcome Scale (GOS), and dichotomized into "favorable" (GOS score 4-5, moderate or low disability) and "unfavorable" (GOS score 1-3, severe disability, persistent vegetative state or death).
Statistical Analysis
A multilevel mixed-effects logistic regression was used to assess the association between the abovementioned explanatory variables on both mortality and neurological outcome 3 months after SAH. First-level and second-level covariates in the hierarchical models were individual patients and national socioeconomic indicators of the country of treatment, respectively. Two separate generalized linear mixed models, fit by the Laplace approximation, were generated for each of the 2 response variables. All explanatory variables, with the exception of country, were treated as fixed effects in the model, because their influence on outcomes for individual patients was not expected to vary between countries. Country of treatment was included in the model as a random effect, a variable that does not have a reproducible and fixed influence on individual outcomes. The mixed-effects logistic regression for mortality is shown below: logit(mortality ij ) = b 0i + b 1i (x 1 ) + b 2i (x 2 ) +…+b 21i (x 21 ) + b 22j (country) The subscript letter "i" refers to the "i'th" individual patient in the "j'th" country. b 0 is the fixed intercept while b are the slope terms for each of the fixed-effect explanatory variables x 1-21 ; b 22j = b 22 + μ 22j , where μ 22j is the random variation from the j'th country.
All discrete explanatory variables were dichotomized, as described in the relevant sections. Odds ratios (ORs) and their 95% confidence intervals (CIs) are reported for each discrete explanatory variable, with thresholds of significance set at p < 0.05. Age, time to surgical clipping, funding model, per-capita GDP, population-to-neurosurgeon ratio, and neurosurgical centers per population were continuous explanatory variables. The absolute value of ORs are not as informative for continuous independent variables, where they tend to approach 1; hence Wald statistics were generated for each of these variables, and compared with a standard chi-square distribution with 1 degree of freedom. Wald statistics greater than 3.84 correspond to a p value < 0.05.
The magnitude of influence of a random effect on the response variable is measured not by the absolute value of the random effect, but rather its variance, i.e., the variance in the μ 22 term, which was quantified by 2 different measures. The first measure is the intraclass correlation coefficient (ICC), the traditional metric used to quantify the percentage of total variation in the independent variable attributed to variation in the random effect. 37 The second measure is the median OR, which always has a value ≥ 1.
The median OR quantifies the variation between secondlevel covariates by comparing 2 persons chosen randomly from different countries. A median OR of 1 indicates no variation between second-level covariates (countries), while larger values denote significant variation. 26, 27 The measure is also highly informative because it is directly comparable with fixed-effects ORs.
All statistical analysis was performed in R, an opensource statistical computing and graphics platform developed by the R Foundation for Statistical Computing (www.r-project.org).
Results
Patient-and Nation-Level Covariates
Patient-level demographics as well as clinical and radiological characteristics are shown in Table 1 . The majority of patients had a good neurological grade upon presentation (WFNS I-III) and a diffuse radiographic subarachnoid clot. Complications of SAH, such as angiographic vasospasm and hydrocephalus, were noted in nearly half of the patients. Among imputed socioeconomic indicators, nations in the tirilazad studies had a mean per-capita GDP of $24,519 (range $2884-$39,690), a mean population-to-neurosurgeon ratio of 97,550:1 (range 52,000:1 to 330,000:1), and for those nations with data available, a mean of 1.33 neurosurgical centers per million population (range 0.59-2.64). Sixty percent of patients were treated in nations with mixed health care funding systems. No countries possessed an exclusively private model of health care.
Per-Capita GDP, Population-to-Neurosurgeon Ratio, and Neurosurgical Centers per Population
Eighteen explanatory variables (15 from the original tirilazad database and 3 collected socioeconomic indicators) were included as fixed effects in a multilevel logistic regression model with neurological outcome and mortality as dependent variables. Patient-level predictors of mortality were increasing age, angiographic vasospasm (OR 1.70, p = 0.022), IVH (OR 1.43, p = 0.010), incidence of cerebral infarction (OR 4.81, p < 0.001), poor initial WFNS grade (OR 2.96, p < 0.001), ruptured aneurysm size ≥ 25 mm (OR 2.43, p = 0.002), and significant subarachnoid clot burden with diffuse/thick pattern of blood (OR 2.20, p = 0.003). The only nation-level covariate significantly associated with mortality was per-capita GDP, with lower values associated with greater mortality (Table 2) .
Patient-level covariates associated with poor neurological outcome on the GOS included increasing age, ICH (OR 1.65, p < 0.001), IVH (OR 1.57, p < 0.001), incidence of cerebral infarction (OR 7.38, p < 0.001), use of HHH therapy (OR 1.35, p = 0.012), history of hypertension (OR 1.35, p = 0.006) or myocardial infarction (OR 2.07, p = 0.024), poor initial WFNS grade (OR 4.16, p < 0.001), ruptured aneurysm size ≥ 25 mm (OR 1.91, p = 0.013), and significant subarachnoid clot burden with diffuse/thick pattern of blood (OR 1.54, p = 0.020). Lower per-capita GDP and a lower population-to-neurosurgeon ratio were nation-level covariates independently associated with poor neurologi-cal outcomes at 3 months following SAH (Table 3) . When the hierarchical model was rerun substituting populationto-neurosurgeon ratio with neurosurgical centers per population, for those countries with available data, greater neurosurgical centers per population was associated with worse GOS outcomes (p < 0.001). Among socioeconomic variables, health care funding model did not significantly impact either primary outcome.
Heterogeneity Among Countries of Treatment
Country of treatment possessed a variance of 0.031 in the model assessing neurological outcome and 0.057 in the model for death. Median ORs were calculated to quantify the variation between countries (i.e., secondlevel variation). The median OR was calculated to be 1.18 and 1.26 for neurological outcome and mortality, respectively. Because the median OR is directly comparable to ORs calculated for fixed effects, it can be observed that intercountry variation had a lesser impact on the primary outcomes than individual predictors identified in the logistic regression model.
The calculated ICCs for neurological outcome and death were 3% and 5.3%, respectively. That is, 3% of the total variation in neurological outcome and 5.3% of the total variation in death were attributable to the country of treatment, with the remainder attributed largely to patient-and nation-level covariates that were evaluated as fixed effects in this model. Both median OR values and ICCs suggest that the influence of country of treatment on both primary outcomes is important but explains less of the variance in the data relative to patient-level covariates. Heterogeneity in mortality and neurological outcome based on country of treatment can be demonstrated visually on a forest plot, which depicts the differences in the empty model intercepts across different countries (Figs. 1 and 2 ).
Discussion
Aneurysmal SAH is associated with significant morbidity and mortality, with reported case fatality rates ranging from 20% to 50%. 31 We have demonstrated that national socioeconomic indicators, including per-capita GDP and population-to-neurosurgeon ratio, contribute partly to regional disparities in outcomes. These findings may provide a basis upon which national economic and health policies may be optimized to improve outcomes following aneurysmal SAH.
With respect to per-capita GDP, it may be expected that wealthier nations, with greater infrastructure to accommodate critical care and rehabilitation facilities, would perform better on metrics of health outcome, particularly following resource-intensive acute illnesses such as SAH. Better outcomes in countries with higher GDP may also be a reflection of certain aspects of care outside the hospital, rather than direct patient care. For instance, more efficient systems for diagnosis and transfer of patients may directly translate to better outcomes. While the impact of GDP on outcome following SAH has not been previously studied, others have investigated its effects on outcomes following other acute illnesses, including ischemic stroke and myocardial infarction.
9,39 After adjusting for the increased incidence of both pathologies in populations with lower per-capita GDP and lower percapita health expenditure, the age-adjusted case fatality rate remained higher in populations with lower per-capita GDP. The current study may be the first to demonstrate a similar trend in patients with aneurysmal SAH.
A higher population-to-neurosurgeon ratio was also found to be associated with better neurological outcomes * Denotes significance at p < 0.05. Dichotomized variables are contrasted with "no" unless otherwise specified.
in the current analysis. This finding must be interpreted in the context of the countries studied, which had a population-to-neurosurgeon ratio ranging from 52,000:1 to 330,000:1. These results could indicate that centralized neurosurgical care, with fewer but higher-volume hospitals servicing a given area, may provide better outcomes following SAH, particularly in developed countries, as is the case with the majority of nations included in the tirilazad study. An association between higher per-center SAH volumes and lower operative complication rates would be most supportive of centralized care contributing to improved outcomes. These data were not available from the tirilazad database; however, fewer neurosurgical centers per population may be a reasonable indicator of more centralized care, and this variable was indeed associated with improved neurological outcome in the current study. The association between centralization of care and improved outcomes has been suggested by a variety of smaller studies from the US in patient populations with both ruptured and unruptured intracranial aneurysms, as well as other neurosurgical conditions. 2, 6, 16, 32 The type of national health care funding model was not significantly associated with either primary outcome in the current analysis. One explanation is that health care funding model does not influence outcome after SAH. Another explanation is that differences between public and private funding models within individual countries are diminished when countries with both systems are coded as mixed. Indeed, the majority of nations in the tirilazad studies used mixed models, and there were no nations that had a purely private funding system, which reduced the variance in health care funding models in this sample. Furthermore, the majority of countries in the tirilazad studies were developed nations. Disparities between public and private sectors are often exacerbated in developing nations, where inequalities in access to resources and physician training are greater. 3, 4 In our previous analyses of the tirilazad studies we reported that while treatment differences do exist between countries, particularly in antiepileptic drug use and hyperdynamic therapy protocols, the country of origin itself was not an independent predictor of outcome in a conventional multivariate analysis. 28 However, such analyses have been limited by the choice of statistical models. Given that heterogeneity exists in patient outcomes across different countries, considering patients within a given country as clusters nested within countries in a mixedeffects model may be superior to conventional regression, which views all subjects as independent observations. Analysis of country-level variation using a hierarchical, or multilevel, mixed-effects approach may be advantageous, as it permits theoretical modeling of covariates that may explain this variance. 33 Unlike conventional regressions, mixed-effects approaches do not assume complete independence of all individual observations, nor a normal distribution for the response variables. In our hierarchical analysis, country of treatment was assessed as a random effect to account for intercountry variation in applications of treatment protocols. Both metrics used to quantify the variability in this random effect-the ICC and the median OR-suggest that country of treatment does impact both mortality and neurological outcome, but to a lesser extent than patient-level factors such as initial neurological grade or the incidence of cerebral infarction.
An important limitation of our study is the fact that the tirilazad data are now dated, and restricted to an era prior to the widespread adoption of endovascular techniques to secure ruptured aneurysms. Furthermore, we were limited in our ability to make strong conclusions about the effect of centralization of care due to the lack of data regarding SAH case volumes and complication rates at individual centers. Significant associations identified in the current work should inform future studies, upon which appropriate public policy may be formed to mitigate the morbidity associated with ruptured intracranial aneurysms. Finally, it should be recognized that the associations described in the current study do not reflect practices at individual treatment centers, but rather largescale trends in a large cross-national database.
Conclusions
Disparities in case fatality rates following SAH between different regions have been documented. 31 The current study modeled nation-level socioeconomic indicators that may explain these differences. We found that national socioeconomic indicators, such as higher per-capita GDP and higher population-to-neurosurgeon ratio, are associated with reduced mortality and better outcome after aneurysmal SAH, and contribute to regional disparities in outcomes. National economic and health policies aimed at improving fiscal outlook and health expenditures, as well as centralizing neurosurgical and acute care facilities, may yield meaningful gains in improvement of outcomes following aneurysmal SAH.
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Dr. Macdonald receives grant support from the Physicians Fig. 1 . Forest plot of heterogeneity in empty model intercept for mortality according to country. Considerable heterogeneity existed in mortality by country. Numerous patient-level and nation-level covariates may explain such heterogeneity. Russia and South Africa were excluded from the model due to few independent observations and very wide CIs, respectively.
Fig. 2.
Forest plot of heterogeneity in empty model intercept for GOS score according to country. Heterogeneity existed in neurological outcome based on the GOS score by country, which may be explained by both patient- and nation-level covariates. Russia was excluded from the model due to few independent observations.
